EA200400872A1 - Лечение рассеянного склероза козьей сывороткой - Google Patents

Лечение рассеянного склероза козьей сывороткой

Info

Publication number
EA200400872A1
EA200400872A1 EA200400872A EA200400872A EA200400872A1 EA 200400872 A1 EA200400872 A1 EA 200400872A1 EA 200400872 A EA200400872 A EA 200400872A EA 200400872 A EA200400872 A EA 200400872A EA 200400872 A1 EA200400872 A1 EA 200400872A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
multiple sclerosis
goat serum
goat
suited
Prior art date
Application number
EA200400872A
Other languages
English (en)
Other versions
EA014287B1 (ru
Inventor
Джонатан Хини
Ангус Дж. Далглиш
Стэнли Д. Т. Уайт
Original Assignee
Эймско Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/003037 external-priority patent/WO2003004049A2/en
Application filed by Эймско Лимитед filed Critical Эймско Лимитед
Priority claimed from PCT/GB2003/000342 external-priority patent/WO2003064472A2/en
Publication of EA200400872A1 publication Critical patent/EA200400872A1/ru
Publication of EA014287B1 publication Critical patent/EA014287B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)

Abstract

Сывороточная композиция, полученная от козы, иммунизированной ВИЧ, содержит анти-HLA антитело и подходит для паллиативного улучшения состояния животного.Отчет о международном поиске был опубликован 2003.09.04.
EA200400872A 2002-01-28 2003-01-28 Способ лечения заболевания двигательных нейронов козьей сывороткой EA014287B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0201896.8A GB0201896D0 (en) 2002-01-28 2002-01-28 Treatment
PCT/GB2002/003037 WO2003004049A2 (en) 2001-07-02 2002-07-02 Use of polyclonal anti-hiv goat serum as a therapeutic agent
PCT/GB2003/000342 WO2003064472A2 (en) 2002-01-28 2003-01-28 Treatment of ms with goat serum

Publications (2)

Publication Number Publication Date
EA200400872A1 true EA200400872A1 (ru) 2005-02-24
EA014287B1 EA014287B1 (ru) 2010-10-29

Family

ID=9929866

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400872A EA014287B1 (ru) 2002-01-28 2003-01-28 Способ лечения заболевания двигательных нейронов козьей сывороткой

Country Status (13)

Country Link
US (2) US20110086046A1 (ru)
KR (1) KR20040090995A (ru)
CN (1) CN1674936A (ru)
AT (1) ATE478682T1 (ru)
BR (1) BR0307242A (ru)
DE (1) DE60333898D1 (ru)
DK (1) DK1469882T3 (ru)
EA (1) EA014287B1 (ru)
ES (1) ES2351305T3 (ru)
GB (1) GB0201896D0 (ru)
IL (3) IL199681A (ru)
NZ (1) NZ534288A (ru)
PL (1) PL213386B1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
EP0800534A2 (en) * 1994-12-23 1997-10-15 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
JPH11506336A (ja) * 1995-06-07 1999-06-08 コノート ラボラトリーズ リミテッド 免疫系選択細胞への抗原送達のためのキメラ抗体
WO1997002839A1 (en) * 1995-07-13 1997-01-30 Gkc Research, Inc. Viral suppression, treatment and prevention of viral infections
GB9619894D0 (en) * 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
PL352159A1 (en) * 1999-05-24 2003-07-28 Sankyo Co Pharmaceutical compositions containing antibody against the fas
AU2001275696A1 (en) * 2000-07-21 2002-02-05 Ice Biologics Limited Therapeutic agent
IL159682A0 (en) * 2001-07-02 2004-06-20 Aimsco Ltd Use of polyclonal anti-hiv goat serum as a therapeutic agent

Also Published As

Publication number Publication date
NZ534288A (en) 2006-04-28
ES2351305T3 (es) 2011-02-02
GB0201896D0 (en) 2002-03-13
IL199681A0 (en) 2011-08-01
BR0307242A (pt) 2004-12-14
PL213386B1 (pl) 2013-02-28
PL373771A1 (en) 2005-09-19
KR20040090995A (ko) 2004-10-27
IL221566A (en) 2013-11-28
US20110086046A1 (en) 2011-04-14
CN1674936A (zh) 2005-09-28
EA014287B1 (ru) 2010-10-29
US20130195890A1 (en) 2013-08-01
IL221567A (en) 2013-11-28
DE60333898D1 (de) 2010-10-07
DK1469882T3 (da) 2010-12-13
IL199681A (en) 2013-11-28
IL221566A0 (en) 2012-09-24
ATE478682T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
DE60327205D1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
ATE479710T1 (de) Bispezifische antikörper
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
DE69433406T2 (de) Antikörper gegen cd40
NZ568769A (en) Human monoclonal antibodies against CD20
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
AU9399501A (en) Therapeutic antibodies
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
ATE408624T1 (de) Verfahren zur reinigung von fsh
NZ602256A (en) Monoclonal antibodies against the rgm a protein and uses thereof
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
WO2003064472A3 (en) Treatment of ms with goat serum
ATE442860T1 (de) Mikropartikel mit cd28-spezifischen monoklonalen antikoerpern
NO20051715L (no) HCV assay
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
DK1200126T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til fremstilling af en farmaceutisk sammensætning til behandling af virusinfektioner
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
ES2165506T3 (es) Antagonistas del il-8 para el tratamiento del asma.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
EA200400872A1 (ru) Лечение рассеянного склероза козьей сывороткой

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU